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1 MATERIALS 
As part of the Metabric (Molecular Taxonomy of Breast Cancer International Consortium) 
study, transcriptomic data from over 2000 breast tumours was generated, with full details of 
the patient population available in the accompanying publication 1.  The data is available 
through the European Genome-phenome archive (https://www.ebi.ac.uk/ega/home) under 
study ID EGAD00010000162 – Illumina HT 12 IDATS. The microarray platform used in the 
Metabric study was the Illumina HumanHT 12v3 beadchip.  
The human genome scale metabolic network (GSMN) Recon 2 has been downloaded from its 
public repository (http://humanmetabolism.org/2).  
2 METHODS 
2.1 Transcriptomic data pre-processing 
Raw transcriptomic data was first pre-processed to remove data from bad quality probes, 
normalize expression levels across bead arrays and summarize probeset data to derive 
expression levels for each target gene. All data manipulation and analysis were performed 
using scripts written in the R statistical programming language and the Bioconductor3 and 
RStudio 4 interfaces. 
2.1.1  Data import and pre-processing 
Transcriptomic data within the Metabric dataset was generated using the Illumina HumanHT-
12 v3 platform. The Bioconductor package beadarray was used to import raw images, 
generate quality assessment information, carry out image processing to adjust for spatial 
artefacts, and undertake background correction. Probes were then filtered by detection score, 
with a cut off p-value set as 0.01 3,5  
2.1.2 Probe annotation 
The Bioconductor package illuminaHumanv3.db was used to provide a mapping between the 
Illumina probe identifiers and common gene symbol identifiers 5.  
2.1.3 Determination of gene expression presence/absence from pre-
processed transcriptomic data 
Following pre-processing, transcript levels were classified as absent or present based on 
detection calls. This classification removes the potential bias associated with the arbitrary 
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thresholds required for setting discrete gene expression states (down-regulated, unaffected, 
up-regulated).  
We note that each transcript can be detected by multiple probe sets, and one probe set can 
identify more than one target gene. Hence, it is necessary to weight presence/absence calls 
against the specificity of the probesets. Genes were considered to be present if half or more 
probes for a given probeset were detected. Probes detected as present were assigned a value 
of 0; absent probes were assigned value of -1. If the mean for all probes in a given probset 
was higher than -0.5 the gene was considered expressed and not expressed otherwise.  
2.2 Creation of personalized GSMNs using transcriptome data 
The presence/absence calls for the expression of each gene on the Illumina beadarray 
were analysed in the context of Recon2 Genome Scale Metabolic Network (GSMN) to derive 
personalised metabolic landscapes for each sample. Recon2 is the most comprehensive 
reconstruction of global human metabolism, encompassing 5,063 metabolites interconverted 
through 7,440 unique reactions 2. The list of metabolic reaction formulas is derived from the 
repertoire of metabolic enzymes encoded in human genome. The dependence of a reaction on 
the genes encoding protein subunits of an enzyme catalysing this reaction is expressed as a 
Boolean gene-reaction association rule. Here, we have downloaded a Systems Biology 
Markup Language (SBML) file from http://humanmetabolism.org/, which defines 
metabolites, reactions and gene-reaction association rules. The SBML file has been imported 
into version 2 of our SurreyFBA software, which was subsequently used for all simulations 
described below.  
We used a modified version of the iMAT method of Shlomi and colleagues 6 to 
integrate transcriptomic presence/absence call data with Recon 2 model and derive metabolic 
landscapes. The iMAT uses well-established Constrained Based Modelling (CBM) approach, 
where whole-cell metabolic model is simulated at steady state. The variables of the model are 
reaction fluxes rather than metabolic concentrations. The metabolic reaction formulas are 
used to create stoichiometric constraints, where for each metabolite the sum of fluxes 
producing and consuming this metabolite equals 0. Additional thermodynamic constraints are 
created using information about reaction reversibility. Transcriptome data are then discretised 
into three levels: -1, 0 and 1 described as “lowly”, “moderately” and “highly” expressed 
genes in original publication. Discretised data are used to identify a subset of reactions in 
GSMN, which are metabolically active for a particular pattern of gene expression. The iMAT 
searches for the reaction sets, which are maximally congruent with transcriptome data in 
terms of following criteria: i) all stoichiometric and thermodynamic constraints are satisfied 
ii) maximal number of reactions associated with “lowly” expressed genes is excluded from 
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the result iii) maximal number of reactions associated with “highly” expressed genes is 
included into solution. The trivial solution including all reactions associated with highly 
expressed genes and excluding all reactions associated with “lowly” expressed genes usually 
violates stoichiometric and thermodynamic constraints. Thus, the iMAT performs Mixed 
Integer Liner Programming (MILP) optimisation to find a set of reactions satisfying all 
constraints and matching maximal number of reactions with associated gene expression 
status. There may be multiple reaction sets satisfying optimisation objective to the same 
extent. To address this problem iMAT determines how activity of each reaction affects the 
solution. This requires execution of two MILP optimisations for each reaction. The final 
result is classification of each reaction as active in all alternative solutions, inactive in all 
alternative solutions or undetermined. Detailed formulation of iMAT is given elsewhere and 
will not be re-iterated here. 
The MILP is computationally expensive as a single solution requires iterative 
execution of multiple Linear Programming (LP) optimisations of the entire GSMN model. 
Since iMAT executes two MILP optimisations for each reaction, the iMAT analysis of a 
single transcriptome sample in the context of Recon 2 requires 14,880 MILP optimisations. 
We have found that iMAT is too computationally expensive to analyse each of the 2000 
transcriptome samples in METABRCIK dataset. To address this issue, we have modified 
iMAT such that only one MILP solution per transcriptome sample is needed, thus increasing 
the computational efficiency. Since we use gene expression data to identify, which reactions 
in the GSMN are non-active we name our approach Gene Expression Based Reaction 
Activity (GEBRA). 
The GEBRA uses discretized expression data as input. However, contrary to iMAT 
we use two rather than three levels and use detection calls rather than array signal (see 2.1.3 
above). As argued in main manuscript this is more robust as no arbitrary threshold on array 
signal is required. Thus, the genes which transcripts are absent are assigned -1 and genes 
which transcripts are present are assigned 0. Subsequently, for each reaction i the gene-
reaction association rules are used to calculate reaction state denoted by si. The gene names 
are replaced by levels from {-1, 0} and logical “and” and “or” operators are replaced with 
max and min operations respectively. Resulting reaction states also assume -1 or 0. We note 
that encoding as -1 or 0, rather than logical “true” or “false” is convenient as the resulting 
state si can be directly used as coefficient of objective functions: reactions with state -1 will 
contribute negatively to the objective, other reactions do not contribute at all. The GEBRA 
searches for stoichiometrically and thermodynamically feasible metabolic models, where the 
maximal number of reactions associated with absent genes is non-active. 
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  After reaction states are determined, reactions are classified as forward (lower 
bound flux 𝑣"#$	 ≥ 0) denoted as 𝑣# with state 𝑠# where 𝑖 ∈ 𝑅, (forward reaction set), reverse 
reactions (upper bound flux 𝑣"-.	 ≤ 0 ) denoted as 𝑣0  with state 𝑠0  where 𝑗 ∈ 𝑅2  (reverse 
reaction set), and reversible reactions (𝑣"#$	 < 0 and 𝑣"-.	 > 0) denoted as 𝑣5 with state 𝑠5 
where 𝑘 ∈ 𝑅,2  (reversible reaction set). Each reversible reaction is divided into a forward 
direction denoted 𝑣57 , and a reverse direction denoted 𝑣58  , both having the state 𝑠5 . 
Subsequently the MILP problem defined by the following equations is solved: 
										𝑚𝑎𝑥<=,<?,<@A,<@B,CA,CB	(	 (𝑠# ∙#∈FG 	𝑣#) −	 (𝑠0 ∙0∈FJ 	𝑣0)	+	 𝑠5 ∙ (𝑣57 +5∈FGJ	 𝑣58)	)	 [1]	
subject to the constraints: 
																𝑆	×𝑣 = 0,			𝑆 ∈ 𝑅$×", 𝑣 ∈ 𝑅"						 																															[2]	
								𝑣"#$	 ≤ 𝑣	 ≤ 	 𝑣"-.		 	 	 	 		[3]	
		𝑣57 	+ 	𝑏	 ∙ 	𝑣"-.	 ≤ 𝑣"-.			 	 	 	 		[4]	
															𝑣58 	+ 	𝑏	 ∙ 	𝑣"#$	 ≤ 0	 	 	 	 	 		[5]	
																𝑏 ∈ [0, 1]		 	 	 	 																															[6]	
	
Eqn 1 defines the objective function of the MILP problem. Eqn 2, defines stoichiometric 
constraints and flux balance relations at steady state, where 𝑆 is a 𝑛×𝑚 stoichiometric matrix 
with 𝑛 metabolites and 𝑚 reactions and 𝑣 is a vector of 𝑚 reaction fluxes. Eqn 3 defines flux 
bounds that express reaction reversibility (thermodynamic constraints) and boundary 
conditions i.e. the set of active extracellular nutrient transporters. Here, we used set of 
nutrients defined in Recon 2 model and set Biomass reaction flux to maximal value possible 
in Recon 2, thus requiring that all essential cell components are synthesized. Eqns 4-6 add 
additional constraints and use one Boolean control variable, 	𝑏 , to ensure that for every 
forward/reverse reaction pair only one of the reactions is active at any point, thus preventing 
futile cycles. The solution of this MILP problem provides fluxes for all reactions. The fluxes 
of reactions with state  s = -1 are then constrained to their values obtained in MILP solution. 
The range of fluxes accessible to reactions with state s = 0 is then determined by Flux 
Variability Analysis (FVA). Each reaction subjected to FVA becomes objective function and 
its minimal and maximal value is determined by two Linear Programming (LP) optmisations. 
The LP is much faster then MILP, thus computational cost remains acceptable. At the end of 
this step each reaction is assigned a flux range 	 𝐹"#$, 	𝐹"-.	 . Reactions with state = 0 are 
assigned FVA ranges, reactions with state -1 have minimal and maximal flux equal to MILP 
solution. The final output of GEBRA is reaction activity determined by classification of flux 
ranges. If 𝐹"#$ = 	𝐹"-. = 0 then the reaction is predicted to be inactive and assigned activity 
of -1; otherwise, the reaction is predicted undetermined and assigned activity of 0. The final 
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solution, which we call a metabolic landscape is vector a of m elements, where ai is activity of  
ith reaction, either -1 (non-active) or 0 (undetermined). In other words, we determine a set of 
inactive reactions, such that as many reactions associated with absent transcripts (s = -1) are 
declared to be non-active (a = -1) as it is possible without violation of GSMN constraints. 
Our GEBRA method is based on the “congruency” principle of iMAT, but uses 
results of single MILP solution instead of two MILP solutions for each reaction. In order to 
evaluate to what extent this assumption affects assignment of non-active reactions we 
compared GEBRA with iMAT by analysis of the transcriptome data for NCI-H23 cell line 
derived from a non-small cell lung carcinoma 7,8. To enable comparison we used only two 
gene expression levels (“low”, “medium”) in iMAT. Full details of the comparison are 
presented as supplementary table S5, with major points noted here. Analysis between the two 
approaches revealed a statistically significant overlap of 2036 reactions predicted by both 
GEBRA and iMAT, with a prediction accuracy of 92% (p=4.3e-20). Critically, the GEBRA 
approach was computationally much more efficient than the original approach. Using the 
same computational cluster, analysis of the NCI-H23 transcriptome took 59725 seconds using 
the original iMAT approach, but only 752 seconds using GEBRA; hence, GEBRA approach 
was nearly 80-times faster than the original method, while generating results which were 
nearly identical to original congruency method. The gain of computational efficiency enabled 
the first generation of personalised GSMNs for all 2000 tumours in METABRICK dataset 
and discovery of metabolic reprogramming features that were validated experimentally. 
2.3 Clustering of personalized GSMNs 
To identify clusters of similar personalized GSMNs for breast cancer, K-means clustering 
was performed using the R package clValid 9.  The input data for clustering consisted of 2000 
GSMNs (cases) characterized by 7440 reactions states (variables). A range of clusters from 5 
to 10 was investigated, consistent with the 10 clusters previously identified from 
transcriptome analysis in the original Metabric publication 1.   K-means clustering identified a 
stable, statistically significant cluster that was associated with poor patient prognosis, as 
determined by the cluster analysis package fpc. We have also performed hierarchical 
clustering. A statistically significant cluster of personalized GSMNs associated with poor 
patient prognosis was also identified by this approach. However, cluster stability was shown 
to be poor through bootstrap analysis.  
In summary, we demonstrate that a poor prognosis cluster can be successfully recovered and 
is stable when K-means clustering method is used. This cluster is reproducible using a second 
clustering approach, although with a lower degree of robustness. Analysis of the personalized 
GSMNs derived from the Metabric confirmatory dataset by both K-means and hierarchical 
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clustering approaches identified a poor patient prognosis cluster, with this cluster being more 
robustly derived by K-means clustering, again. 
2.4 Differential gene expression 
Gene expression profiles used to derive personalized GSMNs within the poor patient 
prognosis cluster were compared to all other gene expression profiles within the Metabric 
discovery set. Differential gene expression was performed using the beadarray and limma 
packages5,10, with functional clustering analysis undertaken in DAVID11. Statistical over-
expression approach is a standard methodology to analyze transcriptomic datasets, and allows 
comparison between the two approaches: statistical over-representation versus personalized 
GSMN prediction 
2.5 Statistical Analysis 
Pairwise t-test and Wilcoxon signed-rank test was performed using GraphPad Prism (v6), and 
the R-packages splines, survival and pvclust3,12. Binomial probability confidence intervals 
were calculated using:  http://www.danielsoper.com/statcalc3/calc.aspx?id=85.  
 
3 SUPPLEMENTARY FIGURES 
3.1 Figure S1: Breast cancer cell lines express the major components 
for serotonin production and a range of serotonin receptors  
3.1.1 Methods 
For in vitro analysis of DDC and Tph1/2 expression in breast cancer cell lines, SHSY5Y, 
MDA-MB-231, MCF7 and SKBR3 cells were cultured in 6-well plates at a density of 1x106 
cells per well in Dulbecco’s Modified Eagle Medium with 2 mM L-glutamine, 4.5 g/L 
glucose, 100 units/ml penicillin, 0.1mg/ml streptomycin sulphate, 0.25µg/ml amphotericin B 
and 10% foetal bovine serum (FBS), at 37˚C and 5% CO2.  
Western blot analysis was undertaken as previously described13. Briefly, total protein was 
extracted using RIPA buffer, and protein level quantified by the method of Lowry14. Thirty 
micrograms of total proteins was separated on precast 6-18% polyacrylamide gels, and then 
transferred to PVDF membrane. Membranes were blocked (1 hour) in 5 % fat free dried milk 
and then probed with primary antibodies against DDC (ab15348) or Tph1/2 (ab17934) for 
one hour, followed by anti-rabbit (1:10000) or anti-mouse IgG (1:10000) IRDye 800 CW 
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secondary, as appropriate, for one hour at room temperature. The membrane was then imaged 
using an Odyssey Family Imaging System (LI-COR Biosciences). 
For in silico analysis of 5-HT receptor expression in breast cancer cell lines, the GSE12777 
dataset contains gene expression profiling of 51 human breast cancer cell lines, and was 
downloaded from the Gene Expression Omnibus (GEO15). Analysis of array output files was 
performed within the Bioconductor R suite3: Data pre-processing was performed using the 
affy package16, and gene expression levels for 24 5-HT receptors extracted. 
3.1.2 Results 
DOPA decarboxylase (DDC) and tryptophan hydroxylase (TPH1/2) are required for the 
production of serotonin from tryptohan (figure S1a). Immunoblotting demonstrates that 
MDA-MB-231, MCF7 and SKBR3 cells all express DDC and TPH1/2, as well as the positive 
control neuroblastoma cell line SHSY5Y (figure S1b). Analysis of transcriptomic data from 
51 human breast cancer cell lines, including those used in the current study, demonstrates 
expression of multiple 5-HT receptors within the cell lines (figure S1c). 
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Figure S1: Breast cancer cell lines express the components for production of serotonin.  
(A) Representation of the serotonin production and detection system within breast cancer 
cells. (B) Total protein from MDA-MB-231, MDF7, and SKBR3 breast cancer cell lines, or 
the positive control cell line SHSY5Y (neuroblastoma-derived) was separated by SDS-PAGE. 
DDC and Tph1/2 protein levels were detected by Western blot; B-actin protein levels were 
also detected to ensure even loading. (C) Transcript levels of 27 5-HT receptors across 51 
breast cancer cell lines were extracted from the GSE12777 dataset, and are presented as an 
expression heat map. 
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3.2 Figure S2: Identification of tumours associated with poor patient 
prognosis requires interpretation of Metabric transcriptomic data 
within the context of a genome-scale metabolic network 
3.2.1 Methods 
For each tumour within the discovery and validation Metabric datasets, the sub-set of genes 
that map to reactions within Recon2 was extracted. These were then classified as -1 (absent) 
or 0 (present) based on Illumina presence/absence calls from the Metabric transcriptomic data 
alone. Hence, while the GSMN was used to identify those genes that map to metabolic 
reaction, network connectivity was not used to generate personalised metabolic landscapes for 
each tumour, or for subsequent clustering. Next, k-means clustering was undertaken using a 
default target of eight clusters, which was previously determined to be optimal.  
3.2.2 Results 
Clustering of the sub-set of transcriptome data that map to metabolic genes within Recon2 
could not recover any cluster significantly associated with poor prognosis for either the 
discovery of validation Metabric datasets. This is consistent with the assertion that a whole-
cell metabolic network context (i.e. the constraints of the entire GSMN model) is key for the 
discovery of the metabolic features of poor prognosis tumours, and the generation of 
mechanistic hypotheses for experimental analysis. 
Figure S2: Clustering of tumour transcriptomes by absence/presence calls alone is 
insufficient to recover a cluster associated with poor patient prognosis. The sub-set of 
reactions mapped to Recon2 metabolic reactions was extracted from the Metabric 
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transcriptome data for each tumour. Genes were classified according to their Ilumina A/P call 
and then subject to k-means clustering  
4 SUPPLEMENTARY TABLES 
Table S1: Differently activated reactions for the poor prognosis clusters derived from 
the discovery and confirmatory datasets show 97% concordance. Personalized GSMNs 
were derived for breast tumours within the discovery (997 sample) and confirmatory (995) 
datasets, as described in methods. K-means clustering analysis reveals a cluster associated 
with poor patient prognosis in both datasets. To test the overlap in these two poor patient 
prognosis clusters, differentially activated reactions were compared using Wilcoxon signed-
rank test. 2198/2273 (97%) differentially activated reactions were concordant between the 
discovery and confirmatory dataset-derived poor patient prognosis clusters, with only 
75/2273 (3%) being different.    
 
Table S2: Differently activated reactions between the poor prognosis cluster and all 
other samples within the discovery dataset. Personalized GSMNs were derived for breast 
tumours within the discovery (997 samples), as described in methods. K-means clustering 
analysis revealed a statistically significant cluster associated with poor patient prognosis. 
DARs between the poor patient prognosis cluster (134 samples) and all other samples (863 
samples) were then identified using flux variability analysis. 
 
Table S3: Differently activated pathways between the poor prognosis cluster and all 
other samples within the discovery dataset. Personalized GSMNs were derived for breast 
tumours within the discovery (997 samples), as described in methods. K-means clustering 
analysis revealed a statistically significant cluster associated with poor patient prognosis. 
DARs between the poor patient prognosis cluster (134 samples) and all other samples (863 
samples) were then identified using flux variability analysis, and separated into DAPs based 
upon identical mean activities within either the poor prognosis group or the remaining 
samples. 
 
Table S4: Differentially expressed genes between poor prognosis cluster and all other 
samples within the discovery dataset. Differentially expressed genes (DEGs) between poor 
prognosis cluster and all other samples within the discovery dataset were identified using the 
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Bioconductor package limma.  For the top 1000 DEGs, the Illumina probe ID, gene name and 
gene ID are presented, along with statistical analysis supporting differential expression. 
DAVID Functional annotation clustering for these DEGs is presented on the second tab. 
 
Table S5: Comparison between iMAT and GEBRA methods. Personalized GSMNs were 
derived from the transcriptomic data for the NCI-H23 cell line against the Recon2 GSMN by 
both iMAT and GEBRA methods. Raw output from each approach is provided in first tab, 
with a direct reaction-by-reaction of activity calls presented in the second tab. Finally, 
comparative statistics are provided in the third tab. 
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